Abstract:Background: Cancer-related cognitive dysfunction (CRCD) is a major functional disorder in patients with cancer. This central nervous dysfunction is found in up to 60 % of patients after tumour therapy, often significantly limits the quality of life and significantly impedes participation in working life. For this reason, diagnosis and treatment of CRCD is of central importance. This narrative review is intended to provide an overview and support for practical clinical care with regard to diagnostics and therapeutic options. Summary: In Germany, CRCD has received insufficient attention in clinical practice due to the lack of guidelines for diagnosis and therapy. The pathophysiology is complex and cannot be explained by chemotherapeutic treatment alone. In addition to the tumour disease as such and the tumour therapy, psychological factors such as anxiety and depression as well as sleep disorders also play a significant role. Today it is known that in addition to age, molecular genetic changes also have an effect on cognitive function. Morphologically, CRCD can be located in the frontal cortex and hippocampus. In addition to easy-to-use screening instruments such as the visual analogue scale (VAS), validated questionnaires such as the Questionnaire of Subjectively Experienced Deficits in Attention (FEDA) developed in Germany are also available. These allow the suspected diagnosis to be substantiated and the patient to be referred to further neurological, neuropsychological or psycho-oncological diagnostics. Within the framework of further neuropsychological diagnostics, the International Cognition and Cancer Task Force (ICCTF) recommends testing learning, memory, processing speed and executive functions. From the authors' point of view, a step-by-step diagnosis is recommended in order to avoid overdiagnosis. In clinical practice, graduation according to the "Common Terminology Criteria for Adversity Events" (CTCAE Version 5.0) is suitable for assessing the degree of severity. Cognitive training should be behaviourally oriented and include regular practice of cognitive skills to restore attention, psychomotor speed, memory and executive functions. The best evidence is currently found for web-based training programmes that can be used by the patient at home. There is also evidence for mindfulness training and physical exercises. In particular, the combination of these three therapeutic elements currently seems to be the optimal treatment strategy for CRCD. Key Messages: Cognitive dysfunction should be given much more attention in the clinical care of cancer patients. Diagnostic tools for this purpose and evidence-based therapeutic interventions are available. In the future, networks should be created that allow for better care of patients with CRCD.

Cancer related cognitive impairment: a downside of cancer treatment

Cancer-related cognitive impairment as a key contributor to psychopathology in cancer survivors: implications for prevention, treatment and supportive care

Long-Term Cognitive Dysfunction in Cancer Survivors

Cancer-related cognitive impairment: updates to treatment, the need for more evidence, and impact on quality of life-a narrative review

Cognitive impairment following breast cancer treatments: an umbrella review

Cognitive impairment after cancer treatment: mechanisms, clinical characterization, and management

A narrative review of risk factors and interventions for cancer-related cognitive impairment

Cancer-Related Cognitive Impairments (CRCIs) in Non-Central Nervous System Adult Patients: Outcome Measures and Methodology of Assessment: A Literature Review

Neuroimaging Advances in Chemotherapy-Related Cognitive Impairment: from Clinical to Preclinical Research

Neuroimaging biomarkers and cognitive function in non-CNS cancer and its treatment: Current status and recommendations for future research

Chemobrain in Breast Cancer: Mechanisms, Clinical Manifestations, and Potential Interventions

Radiation-Induced Cognitive Decline: Challenges and Solutions

Seeing through "brain fog": neuroimaging assessment and imaging biomarkers for cancer-related cognitive impairments

Self-reported cancer-related cognitive impairment is associated with perturbed neurotransmission pathways

Cancer related cognitive dysfunction - A narrative review for clinical practice

Chemotherapy-induced cognitive impairment and its long-term development in patients with breast cancer: results from the observational CICARO study

The National Cancer Institute Clinical Trials Planning Meeting to Address Gaps in Observational and Intervention Trials for Cancer-Related Cognitive Impairment

Impact of Cognitive Rehabilitation on Cognitive and Functional Outcomes in Adult Cancer Survivors: A Systematic Review

Treatment of Radiation-Induced Cognitive Decline in Adult Brain Tumor Patients

Cancer-related cognitive impairment: current perspectives on the management of cognitive changes following cancer treatment

Cancer-related cognitive impairment in older adults with acute myeloid leukemia treated with hypomethylating agents and venetoclax chemotherapy: a longitudinal descriptive study